Lexeo Therapeutics LXEO

Lexeo Therapeutics, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)

$2.96+0.34%close on Nov. 20, 2026 · volume 1.8M · Yahoo Finance

Price, last 64 sessions

$3.00$4.00$5.00Sept. 2026Oct. 2026Nov. 2026
Aug. 24, 2026 to Nov. 20, 2026 · high $5.13 · low $2.63 · SEC filing, placed when SEC released it

Our coverage

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Nov. 17, 2026Louis Edward Tamayo
Chief Financial Officer
Sold1,007$3.26$3,283
Nov. 17, 2026Jose Manuel Otero
Chief Operating Officer
Sold1,285$3.26$4,189
Nov. 17, 2026Richard Nolan Townsend
Chief Executive Officer, director
Sold3,295$3.26$10,742
Aug. 18, 2026Louis Edward Tamayo
Chief Financial Officer
Sold4,117$4.91$20,203
Aug. 18, 2026Richard Nolan Townsend
Chief Executive Officer, director
Sold3,345$4.95$16,562
Aug. 18, 2026Jose Manuel Otero
Chief Operating Officer
Sold1,304$4.96$6,464

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 30 →
  • 4Nov. 18, 2026, 5 p.m. ETView on SEC.gov
  • 4Nov. 18, 2026, 5 p.m. ETView on SEC.gov
  • 4Nov. 18, 2026, 5 p.m. ETView on SEC.gov
  • 4Nov. 17, 2026, 5:56 p.m. ETView on SEC.gov
  • SCHEDULE 13G/ANov. 16, 2026, 12:24 p.m. ETView on SEC.gov
  • 10-QNov. 16, 2026, 7:05 a.m. ETView on SEC.gov
  • 8-KNov. 16, 2026, 7:02 a.m. ETView on SEC.gov

    Results of operations and financial condition · Regulation FD disclosure · Other events · Financial statements and exhibits

    AI summary, unreviewedLexeo Therapeutics Q3 2026 net loss of $0.43 per share misses $0.32 consensus, while LX2020 interim data show 80% NSVT reduction

  • SCHEDULE 13G/ANov. 16, 2026, 6:06 a.m. ETView on SEC.gov